
Biomednewsbreaks - Lantern Pharma Inc. (NASDAQ: LTRN) Highlights LP-184 Preclinical Success In Pediatric Brain Cancer ...
(MENAFN- Investor Brand Network) Lantern Pharma (NASDAQ: LTRN) reported strong preclinical results for LP-184 in atypical teratoid rhabdoid tumors (“ATRT”), a rare and aggressive pediatric brain cancer. Presented by Dr. Eric Raabe of Johns Hopkins at the …